Novo Nordisk and Eli Lilly: Price Cuts Aimed at Securing Growth in China!
Reading Time: 4 minutes
The dynamics in the weight loss medication market reach a new level. The two western giants, Novo Nordisk and Eli Lilly, are responding to the intensified competition and rising price pressures in China with substantial adjustments to their pricing models. By 2030, 65% of Chinese people could be overweight A spokesman for Novo Nordisk stated: "We can confirm that we are adjusting our prices for Wegovy in China." Although the company did not provide specific figures, reports from the Chinese economic portal Yicai paint a reliable picture. According...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
